FDA Accepts sNDA for Jardiance in Children 10 to 17 with Diabetes.
In: Formulary Watch, 2023-03-09, S. 1-1
serialPeriodical
Zugriff:
The article focuses on the U.S. Food and Drug Administration (FDA) accepting a supplemental new drug application for Jardiance to lower blood sugar in children with type 2 diabetes. Topics include the expected FDA decision in the second quarter of 2023, the current list price for Jardiance, and the results from the DINAMO phase 3 trial that showed Jardiance to be associated with a statistically significant reduction in participants aged 10 to 17 years with type 2 diabetes.
Titel: |
FDA Accepts sNDA for Jardiance in Children 10 to 17 with Diabetes.
|
---|---|
Zeitschrift: | Formulary Watch, 2023-03-09, S. 1-1 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 2767-3359 (print) |
Schlagwort: |
|
Sonstiges: |
|